---
document_datetime: 2025-11-12 16:33:44
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kisqali-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kisqali-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.8813322
conversion_datetime: 2025-12-21 19:18:56.428609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kisqali

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneedtoalsorefertoEPAR-Proceduralstepstakenandscientific informationafter authorisation(archive).

| Applicationnumber     | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|-----------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN / | B.II.g.5Implementationofchangesforeseen | 20/10/2025                          | N/A                                      | SmPC                            |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII, Labelling,PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000303549                     | in an approved change management protocol - B.11.g.5.a The implementation of the change requires no further supportive data- Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |                        |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation type II / EMA/VR/0000269890 | This was an application for a group of variations. B.I1.b.3 Change in the manufacturing process of the finished product, including an intermediateusedinthemanufactureof the finishedproduct-B.I1.b.3.bSubstantial changestoamanufacturingprocessthat may have a significant impact on the quality, safety andefficacyof themedicinalproduct- Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finishedproduct-B.II.b.5.bAdditionofa new test(s) and limits -Accepted B.II.f.1.bExtensionoftheshelflifeofthe finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product-B.II.f.1.d Changeinstorageconditionsof thefinished productorthediluted/reconstitutedproduct | 18/09/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.f.1 Change in the shelf-life or storage conditions of the finished product-B.II.f.1.e Change to an approved stability protocol - Accepted B.I1.b.3 Change in the manufacturing process of the finished product, including an intermediateusedinthemanufactureof the finished product-B.II.b.3.z Change in the holding time of anintermediate-Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished product - Accepted   |            |      |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type IB / EMA/VR/0000261091 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.zImplementationofan agreed wording, no new data submitted - Accepted C.I.z-To update section5.1 of the SmPC by removing the words\"(excluding microscopic nodal involvement)\" since this wording                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/04/2025 | SmPC |

<div style=\"page-break-after: always\"></div>

| inaccurately reflects the population included in the Pivotal clinical trial (Procedure No. EMEA/H/C/004213/II/0045).   |
|------------------------------------------------------------------------------------------------------------------------|